Login to Your Account



FDA Panel Rejects Vivus Obesity Pill Qnexa

By Donna Young


Friday, July 16, 2010
GAITHERSBURG, Md. – An FDA panel Thursday said the risks of fetal exposure, increased heart rate, depression and other problems outweighed the benefits of weight loss for Vivus Inc.'s Qnexa (phentermine/topiramate). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription